9year low..., page-26

And this from pxs website... So quality of life was not a good enough primary end point for bronchitetasis..

The product is also being developed for use in bronchiectasis, a disease affecting 600,000 globally. Bronchitol will be the first targeted medication for this condition in over 20 years. A Phase 3 clinical trial of Bronchitol in people with bronchiectasis found that it delivered a highly significant improvement in users' quality of life. A second Phase 3 clinical trial is in progress around the world and is studying the effects of Bronchitol on reducing the infectious episodes, antibiotic use and hospitalization stays for patients with bronchiectasis.


http://www.pharmaxis.com.au/bronchitol